Exploring new compounds to enhance a viral therapy for breast cancer treatment
Official title: Development of natural and synthetic compounds as novel potentiators of HSV-1 VC2-GMCSF-based oncolytic viral therapy in Breast Cancer
Funded at Louisiana State Univ A&m Col Baton Rouge · NIH-11247897 · Data updated 2026-11-12
This study is exploring new ways to make a special virus treatment for aggressive breast cancer work better, and it could help patients by using both natural and man-made compounds to boost the therapy's effectiveness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ A&m Col Baton Rouge NIH-funded |
| Lab location | 1 site (Baton Rouge, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $235,497 |
| NIH project number | 5P20GM135000-05 |
| Project ID | NIH-11247897 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with triple-negative breast cancer who have limited treatment options.
✕Less likely to help
Patients with non-breast cancer diagnoses or those with early-stage breast cancer may not receive benefit from this research.
What this research studies
This research focuses on developing both natural and synthetic compounds that can improve the effectiveness of a specific viral therapy targeting breast cancer, particularly the aggressive triple-negative subtype. The approach involves using oncolytic viruses, which are engineered to selectively infect and destroy cancer cells while sparing healthy cells. By inhibiting certain cancer-related signaling pathways, the researchers aim to create a more favorable environment for the viral therapy to work effectively. Patients may benefit from this innovative treatment strategy that combines virology and cancer biology.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with breast cancer, particularly those with triple-negative breast cancer.
How similar studies have gone: Previous research has shown promise in using oncolytic viruses for cancer treatment, indicating that this approach may be viable and beneficial.
Where this research is happening
-
Louisiana State Univ A&m Col Baton Rouge
Baton Rouge, United States Active
Researchers
- Principal investigator: Chamcheu, Jean Christopher — Louisiana State Univ A&m Col Baton Rouge
- Study coordinator: Chamcheu, Jean Christopher
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.